Henry Ford enrolls first patient in GBM AGILE trial
Henry Ford Cancer Institute is first-in-the-world to enroll a patient in the GBM AGILE Trial (Adaptive Global Innovative Learning Environment) – a novel trial design and architecture made possible by an international collaboration of experts in the care of patients with glioblastoma and the design of clinical trials.
Led by the trial sponsor Global Coalition for Adaptive Research (GCAR), GBM AGILE is a seamless Phase II (Efficacy and Safety) / Phase III (Confirmatory) trial aimed at identifying the most effective therapies for patients with glioblastoma, the most aggressive form of brain cancer.
ADAPTING THE TRADITIONAL CLINICAL TRIAL
A next-generation clinical trial program and the first-ever adaptive platform trial for brain cancer, GBM AGILE is a move away from the traditional, one-size-fits-all approach to clinical trials – a major step forward for precision medicine.
“We are launching an era of unprecedented collaboration and advancement in glioblastoma treatment,” says Steven N. Kalkanis, M.D., chairman of the Henry Ford Health Department of Neurosurgery and medical director of the Henry Ford Cancer Institute. “Current treatments have been refined – including surgery, radiation and chemotherapy – but in the era of molecular medicine, dramatic leaps in outcomes through immunotherapy or targeted therapies are yet to be fully realized. With GBM AGILE, those dramatic leaps in outcomes will be more attainable, and at a faster pace, than ever before.”
Traditional clinical trials take three to seven years to produce results, cannot be modified once started, and study only one treatment against the standard of care. GBM AGILE is uniquely designed as a long-standing platform with the ability to test multiple therapies concurrently against a common control (or standard of care). This enables more patients on trial to get access to experimental therapies. Another innovation of GBM AGILE is adaptive randomization, which means it is continuously updated with the latest information. As information accrues, the trial defines subsets of patients more likely to benefit from therapy. Patients are more likely to receive promising therapies at a faster and less costly rate.
“Progress in the treatment of patients with malignant brain tumors has been slow,” says Tom Mikkelsen, M.D., of the Henry Ford Cancer Institute and medical director of the Precision Medicine Program and Clinical Trials Office at Henry Ford Health. “The efficiency, speed and learning of GBM AGILE is intended to allow rapid discovery of better and better treatments for patients with glioblastoma. The era of data-driven innovation has arrived, and it’s being applied to the most difficult problems in cancer therapy.”
A WORLDWIDE EFFORT TO BATTLE GLIOBLASTOMA
GBM AGILE was first conceived in 2015 by an international group of more than 130 clinicians, researchers, biostatisticians, imagers, pathologists, patient advocates, and leaders from government and industry known as the “GBM Knowledge Network”:
- It came together in response to a worldwide effort known as The Cancer Genome Atlas (TCGA), which was launched in 2006 by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).
- The organizations led a nationally coordinated effort to perform a 10-year, deep-dive into the molecular basis of certain kinds of cancers.
- One of the first types of tumors studied in the landmark precision medicine effort was glioblastoma.
- Henry Ford was a major TCGA contributor, nearly 25 percent of all the gliomas studied over the course of the initiative having been donated by Henry Ford’s Hermelin Brain Tumor Center.
Former Vice President Joe Biden has been an outspoken supporter of GBM AGILE and attended the GBM AGILE launch event in November 2015. Biden’s son, Beau Biden, passed away from glioblastoma in May 2015 at the age of 46. Beau had been diagnosed in 2013 and was treated with surgery, chemotherapy and radiation. He suffered a recurrence in the spring of 2015, at which time his condition deteriorated rapidly.
Biden acknowledged the potential of GBM AGILE to offer unparalleled hope for many patients who had previously waited several years to benefit from advances in brain cancer research.
ENROLLING THE FIRST GBM AGILE PATIENT
Henry Ford enrolled GBM AGILE’s first patient in collaboration with GCAR, an international partnership that comprises some of the world’s foremost clinical, translational, and basic science investigators. Through this collaboration and open exchange of ideas, the ultimate beneficiary – the patient – is supported in the fight against rare and deadly diseases.
“This is an important milestone for GBM AGILE and all those involved in this effort, most importantly, the patients, who desperately need new treatment options,” says Dr. Meredith Buxton, Chief Operating Officer of GCAR. “We value the dedication of Dr. Tom Mikkelsen and the team at Henry Ford Cancer Institute to make this trial available to their patients and are eager to continue to work with our other committed study sites and investigators to make this trial available to patients across the United States this year, and internationally in 2020.”
Glioblastoma is one of the deadliest diseases on the planet. When treated with surgery, radiation and chemotherapy, patients have a median life expectancy of 11-15 months. The disease most commonly affects men ages 60 or older, although it can develop at any age in both men and women. The NCI estimates that 22,850 adults were diagnosed with brain and other nervous system cancers in 2015. It also estimates that in the same year, more than 15,000 of those diagnoses resulted in death.
of GBM AGILE is intended to allow rapid discovery of better and better treatments for patients with glioblastoma. The era of data- driven innovation has arrived, and it’s being applied to the most difficult problems in cancer therapy.” – Tom Mikkelsen, M.D.
A LOOK INSIDE THIS ISSUE:
Henry Ford Hospital
2799 West Grand Boulevard
Detroit, MI 48202
Copyright © 2020 Henry Ford Health